Calliditas Therapeutics AB
DelistedCIK 1795579fmd_1F7C3HMR55HAK7KPTJ6DRFPT31Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2024, 13 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|
| Total revenues | – | 185 | 1 | 229 | 803 | 1,207 |
| Cost of revenue | – | – | – | – | 15 | 60 |
| Gross profit | – | – | 1 | 229 | 788 | 1,146 |
| Research and development | 99 | 150 | 241 | 357 | 415 | 502 |
| Selling, general and administrative | 31 | 63 | 142 | 390 | 775 | 1,061 |
| Operating income | (132) | (28) | (380) | (524) | (422) | (373) |
| Interest expense | 0 | 5 | 57 | 9 | 38 | 114 |
| Income before taxes | (132) | (33) | (436) | (513) | (409) | (457) |
| Income tax expense | – | 0 | 0 | (4) | 3 | 9 |
| Net income from continuing operations | – | (33) | (437) | (510) | (412) | (466) |
| Net income | (132) | (33) | (433) | (500) | (412) | (466) |